HBEL (PDE / ADE) Based MACO Calculator

HBEL (PDE / ADE) Based MACO Calculator – Guide

What is Health-Based Exposure Limit (HBEL)?

An HBEL is a scientifically established exposure threshold used to protect patients from adverse effects arising from cross-contamination in shared pharmaceutical manufacturing facilities. HBELs include values such as the Permitted Daily Exposure (PDE) and Acceptable Daily Exposure (ADE), which are derived through a comprehensive toxicological and pharmacological assessment of available non-clinical and clinical data. Regulatory authorities recommend the use of HBELs as the scientific basis for establishing cleaning validation acceptance criteria and risk management strategies.

What is Permitted Daily Exposure (PDE)?

PDE is the maximum quantity of a substance that a patient may be exposed to every day throughout a lifetime without an appreciable risk of adverse health effects. PDE values are established using toxicological data together with uncertainty (adjustment) factors that account for interspecies differences, human variability, study duration, severity of toxicity, and database completeness.

How is PDE determined?

Determination of a PDE involves a structured toxicological risk assessment that includes: (i) hazard identification through a comprehensive review of available pharmacological and toxicological data; (ii) identification of the critical effect(s) relevant to human health; (iii) determination of the point of departure, typically the No-Observed-Adverse-Effect Level (NOAEL), or another scientifically justified value such as the Lowest-Observed-Adverse-Effect Level (LOAEL) or Benchmark Dose (BMD), where appropriate; and (iv) application of appropriate adjustment (uncertainty) factors to account for interspecies differences, human variability, study duration, severity of toxicity, and data quality, resulting in a scientifically justified PDE.

What is MACO and how is it related to HBEL?

Maximum Allowable Carryover (MACO) is the scientifically established acceptance limit used in pharmaceutical cleaning validation to define the maximum quantity of residue from a previous product (such as an active pharmaceutical ingredient (API), excipient, or cleaning agent) that can safely remain on shared manufacturing equipment without posing a risk of cross-contamination or patient harm. Modern MACO limits are derived using a HBEL together with manufacturing parameters including the minimum batch size (MBS) and therapeutic daily dose (TDD) of the subsequent product. This HBEL-based approach provides a scientifically justified, risk-based cleaning limit that aligns with current regulatory expectations.

What is the formula for HBEL-based MACO?

The HBEL-based MACO approach is the internationally accepted scientific method for establishing cleaning validation limits. The commonly applied equation is:

The calculated MACO represents the maximum quantity of residue from the previous product that may be carried over into the next manufactured batch while maintaining patient safety. Depending on company procedures, the MACO may subsequently be converted into equipment-specific residue limits (e.g., mg/cm², mg/swab, or rinse concentration).

To simplify these calculations, you can use our Swab Sample Limit Calculator, Rinse Sample Limit Calculator, and Product Contact Surface Area Calculator.

Why did the pharmaceutical industry shift to HBEL?

Historically, cleaning validation acceptance criteria were often based on arbitrary approaches such as the 10 ppm criterion or 1/1000th of the minimum therapeutic dose. Modern regulatory guidance now recommends scientifically justified HBELs, which are derived from toxicological and pharmacological evidence. This transition improves patient protection, supports Quality Risk Management (QRM), and aligns with current expectations from EMA, PIC/S, WHO, and ICH Q9.

What expert qualifications should a manufacturer verify for HBEL development?

HBELs should be established by qualified professionals possessing expertise in toxicology, pharmacology, or closely related scientific disciplines. Individuals performing PDE or ADE assessments should have experience in interpreting toxicological studies, identifying critical effects, selecting appropriate uncertainty factors, deriving safety limits, and documenting scientific justification. Professional certifications such as Diplomate of the American Board of Toxicology (DABT) or European Registered Toxicologist (ERT) are widely recognized and are considered advantageous by regulatory agencies.

What should you consider when purchasing OEL/PDE monographs?

Selecting a toxicology partner for Occupational Exposure Limit (OEL) and PDE monographs requires prioritizing experienced, certified toxicologists (DABTs/ERTs preferred) and rigorous, multi-step quality assurance processes to ensure accuracy. Key considerations include strict compliance with international regulations (EMA, PIC/S, ANVISA), regular scientific updates, efficient digital ordering systems, ongoing technical support, and a proven track record of industry acceptance.

What is Occupational Exposure Banding (OEB)?

Occupational Exposure Banding (OEB) is a systematic risk assessment approach used to classify pharmaceutical compounds and other chemicals into exposure bands based on their toxicity, potency, and potential health hazards. Each band corresponds to a range of occupational exposure limits and helps determine the appropriate engineering controls, containment strategies, personal protective equipment (PPE), and handling procedures required to protect workers during manufacturing, packaging, laboratory operations, and other activities. OEB is widely used during product development and manufacturing to support safe handling practices, particularly when substance-specific OELs are unavailable.

What are the current regulatory expectations for HBEL-based cleaning validation?

Current international regulatory guidance expects pharmaceutical manufacturers to establish scientifically justified cleaning validation limits based on HBELs. These limits should be incorporated into a documented QRM program, considering equipment design, cleaning processes, product toxicity, residue distribution, analytical capability, and worst-case product selection.

References

• European Medicines Agency (EMA). Guideline on Setting Health-Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities; EMA/CHMP/CVMP/SWP/169430/2012; EMA: London, UK, 2014.
• European Medicines Agency (EMA). Questions and answers on implementation of risk-based prevention of cross-contamination in production and ‘Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012); EMA/CHMP/CVMP/SWP/246844/2018; EMA: London, UK, 2018.
• World Health Organization (WHO). WHO Technical Report Series No. 1033, Annex 2: Points to Consider When Including Health-Based Exposure Limits (HBELs) in Cleaning Validation; WHO: Geneva, Switzerland, 2021.
• Sharma, P.; Marrero, A.; Coates, M.; Henry, B. Automating MACO Calculations in Cleaning Validation. Pharm. Eng. 2021, 41, 60–67.